By Benjamin Horney (May 30, 2018, 4:16 PM EDT) -- Allergan PLC intends to divest its women's health and infectious disease businesses as the company seeks to stop its share price from continuing to fall, according to a Wednesday report from Reuters. According to the report, which cited an interview with Allergan CEO Brent Saunders, the Ireland-headquartered company is planning to make the sales and then refocus on its core businesses of medical aesthetics, central nervous system, eye care, and gastrointestinal products. Saunders was quoted as saying that Allergan has a "very strong pipeline in all those areas" and that focusing on those core businesses will make Allergan a "more exciting company." The infectious disease business could be worth about $1.5 billion, the report said, and the women's health unit could be worth more than $3 billion....